Our commitment

Oblita is committed to the development of new treatments for infectious diseases that are true global health challenges.

Oblita is committed to a One Health approach as it can reduce disparities in health outcomes, especially in low- and middle-income countries, where zoonotic diseases and environmental changes disproportionately affect populations. Environmental changes because of human activities like deforestation, urbanization, and pollution disrupt ecosystems, increasing the risk of disease transmission between animals and humans. Also climate change alters disease patterns, affecting both humans and animals (esp in vector-borne diseases).

Oblita is committed to a One Health approach by focusing on the development of better treatments for zoonotic diseases, like leishmaniasis. It would break the disease’s transmission cycle, improve animal and human health and reducing environmental impacts. Therefor Oblita believes that new veterinary treatments can play a critical role in global health challenges.

Oblita is also committed to public health threats caused by multidrug resistant infectious diseases. This public health threat is not only affecting the poorest and most vulnerable populations (one sixth of the world population suffers from a neglected tropical infectious disease) but also (immunocompromised) patients with serious and life threatening conditions because of multidrug resistant fungal infectious diseases.

Oblita Therapeutics wants to make a difference in the way global health diseases are treated.

FDA Priority-Review Voucher (PRV) Program

D121 is a new chemical entity eligible to receive a Priority Review Voucher upon its approval for the treatment on Leishmaniasis or another Neglected Tropical Disease.

A complete explanation on how the Priority Review Voucher was borne and how it is used can be found on the following website: www.priorityreviewvoucher.org

Qualified Infectious Disease Product (QIPD) is another FDA regulatory incentive to develop new treatments for MDR infectious fungal diseases. D121 might qualify for this designation.

D121 has already received the status of an orphan drug at FDA and EMA.